Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 2-part, randomised, double-blind, placebo-controlled study of the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple ascending doses of FTP 637 in healthy volunteers.

Next Previous
X
Search
Trial Profile

A 2-part, randomised, double-blind, placebo-controlled study of the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple ascending doses of FTP 637 in healthy volunteers.

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs FTP 637 (Primary) ; Interferon alpha-2a
  • Indications Psoriasis
  • Focus Adverse reactions
  • Sponsors Alumis

    • Most Recent Events

    • 22 Oct 2021 Accrual to date is 60 participants as per Australian New Zealand Clinical Trials Registry record.
    • 22 Oct 2021 Planned number of patients changed from 78 to 96.
    • 22 Oct 2021 Planned End Date changed from 20 Jul 2021 to 30 Nov 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top